Neuropharmacology & Psychopharmacology | Multiple Sclerosis & Related Disorders
Efficacy of treatment of patients with relapsing-remitting multiple sclerosis with copaxone (glatiramer acetate) evaluated by brain magnetic resonance spectroscopy
Zinayida Rozhkova, Olena Myalovitska, Tetyana Kobys, Iryna Lobanova*
*Corresponding author: Iryna Lobanova
Department of Neurology, National Medical University, Kyiv, Ukraine
F1000Posters 2012, 3: 877 (poster) [English]
Poster [1.63 MB]
22nd Meeting of the European Neurological Society 2012, 9 - 12 Jun 2012, 480
The aim of our work was to measure the main brain metabolites of a group of 18 patients (10 female and 8 male aged 24-46, the average age 33,2 plus or minus 0,4) with relapsing-remitting MS (RRMS) who were taking copaxone (glatiramer acetate) in the dose of 20mg per day and compare them with metabolite measurements in 20 patients (12 female and 8 male aged 23-40, the average age 31,4 plus or minus 0,7) with RRMS without treatment, which can change the course of multiple sclerosis (MS).
Comparison of metabolic changes that are observed in patients with RRMS in the course of treatment with copaxone (glatiramer acetate), showed that this drug leads to the normalization of cerebral metabolism that is proved by the increase of the N-acetylaspartate to creatine ratio (NAA/Cr) due to the increase of NAA content in the areas of both affected and intact brain tissue. The long term effect of copaxone (glatiramer acetate) consists in restoring axonal links damaged as a result of MS.
No relevant competing interests disclosed.
Please note that most posters on this site present work that is preliminary in nature and has not been peer reviewed.
This poster is open access subject to the CC BY-NC Creative Commons 3.0 License